BTIG Research Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral

BTIG Research lowered shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a report published on Thursday morning, MarketBeat reports.

KROS has been the subject of a number of other research reports. Wells Fargo & Company raised their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Scotiabank initiated coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $95.22.

Keros Therapeutics Trading Down 73.2 %

NASDAQ:KROS opened at $18.43 on Thursday. Keros Therapeutics has a 1 year low of $15.67 and a 1 year high of $73.00. The firm has a 50 day moving average of $59.95 and a 200-day moving average of $52.83.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period in the previous year, the business posted ($1.33) EPS. The business’s quarterly revenue was up 4750.0% compared to the same quarter last year. On average, equities research analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its holdings in Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Keros Therapeutics in the 2nd quarter valued at approximately $1,118,000. Intech Investment Management LLC bought a new position in shares of Keros Therapeutics during the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp raised its holdings in shares of Keros Therapeutics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after purchasing an additional 18,755 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.